Wedbush reiterates Outperform on Cogent Biosciences, $55 target
Wedbush reiterated an Outperform rating on Cogent Biosciences and set a $55.00 price target, implying 68.0% upside versus the Sep 15 close of $32.74.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.